Alphabio Laboratory

Back
Company description
Founded in 1990, Alphabio is one of the largest independent French laboratory in medical biology. To date the Alphabio group includes 20 laboratories. The Group's business is divided between conventional medical biology, hospital biology, specializing and rare biology, quality control department and applied R&D division. Among all laboratory Alphabio sites, 5 sites work closely with health institutions (hospitals and clinics) in Marseille. For this, these sites are located near or in the hospital premises to reduce support time and reporting the results.
Technical platforms have a large number of controllers adapted to the needs of our patients. The European Laboratory, opened in 2013 along with the new European Marseille Hospital has modern premises of 3600 m2 in the hospital. This latest generation technical platform is in continuous operation 24h / 24h, 7 / 7d. We have several technical platforms; some very specialized such as AMP (Assisted Medically Procreation), Somatic Genetic and Molecular Infectiology.

With over 255 employees including 141 technicians and 43 biologists, the group supports about 8 000 patient medical records per week.

Through our clinical trial management expertise and our collaborations with hospital or liberal clinicians and pharmaceutical companies, our R&D department develops first, applied research projects accompanied by prospective clinical trials to identify new diagnostic, prognostic or therapeutic companion markers. Secondly, we performed projects to improve tests or methods performances in the field of infectious diseases.
Product / Services
- Conventional medical biology,
- Hospital biology,
- Specializing and rare biology,
- Applied R&D in the service of personalized medicine.
2016 1. Halfon P, Mohamed S, Penaranda G, Khiri H, Chiche L, Nicolas C, Abergel A. Hepatitis C genotype 4R resistance-associated polymorphisms: The achilles heel of the nonstructural 5A inhibitors? Hepatology. 2016 Aug;64(2):697-8. doi:10.1002/hep.28611. Epub 2016 Jun 1. PubMed PMID: 27118238. 2. Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22. PubMed PMID: 26907973. 3. Dahari H, Halfon P, Cotler SJ. Resurrection of response-guided therapy for sofosbuvir combination therapies. J Hepatol. 2016 May 27. pii: S0168-8278(16)30239-2. doi: 10.1016/j.jhep.2016.05.028. [Epub ahead of print]PubMed PMID: 27242315. 4. Tamalet C, Halfon P, Retraite LL, Grob A, Leandri FX, Heid P, Sancho-Garnier H, Piana L. Genotyping and follow-up of HR-HPV types detected by self-sampling in women from low socioeconomic groups not participating in regular cervical cancer screening in France. J Clin Virol. 2016 May;78:102-7. doi:10.1016/j.jcv.2016.02.027. Epub 2016 Mar 17. PubMed PMID: 27015435. 5. Mohamed S, Bourliere M, Benali S, Oules V, Castellani P, Khiri H, Camus C, Penaranda G, Chiche L, Gonzalez D, Sayada C, Olive D, Halfon P. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure. J Clin Virol. 2016 May;78:36-43. doi: 10.1016/j.jcv.2016.02.022. Epub 2016 Feb 26. PubMed PMID: 26971166. 6. Jarrot PA, Chiche L, Hervier B, Daniel L, Vuiblet V, Bardin N, Bertin D, Terrier B, Amoura Z, Andrés E, Rondeau E, Hamidou M, Pennaforte JL, Halfon P, Daugas E, Dussol B, Puéchal X, Kaplanski G, Jourde-Chiche N. Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (Baltimore). 2016 May;95(22):e3748. doi: 10.1097/MD.0000000000003748. PubMed PMID: 27258503. 7. Lison H, Garioud A, Halfon P, Jambon S, Cordier F, Verbrigghe C, Landgraf N, Pitre C, Nguyen-Khac E, Cadranel JF. Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV-HCV genotype 1 coinfection. Eur J Gastroenterol Hepatol. 2016 Apr;28(4):486-7. doi: 10.1097/MEG.0000000000000508. PubMed PMID: 26934415. 8. Laquière A, Boustière C, Leblanc S, Penaranda G, Désilets E, Prat F. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg Endosc. 2016 Mar;30(3):1242-8. doi: 10.1007/s00464-015-4322-7. Epub 2015 Jul 11. PubMed PMID: 26162420. 9. Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11. PubMed PMID: 27077673. 10. Adhoute X, Penaranda G, Raoul JL, Bourlière M. Hepatocellular carcinoma scoring and staging systems. Do we need new tools? J Hepatol. 2016 Feb 18. pii: S0168-8278(16)00150-1. doi: 10.1016/j.jhep.2016.01.038. [Epub ahead of print] PubMed PMID: 26912407. 11. Adhoute X, Penaranda G, Raoul JL, Bourlière M. "Staging of Hepatocellular Carcinoma: BCLC system, what else!" Liver Int. 2016 Jan 18. doi: 10.1111/liv.13066. [Epub ahead of print] PubMed PMID: 26778275. 2015 12. Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki JP, Bourlière M. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. Eur J Gastroenterol Hepatol. 2015 Dec 21. [Epub ahead of print] PubMed PMID: 26695429. 13. Terriou P, Hans E, Cortvrindt R, Avon C, Charles O, Salzmann J, Lazdunski P, Giorgetti C. Papaverine as a replacement for pentoxifylline to select thawed testicular or epididymal spermatozoa before ICSI. Gynecol Obstet Fertil. 2015 Dec;43(12):786-90. doi: 10.1016/j.gyobfe.2015.10.007. Epub 2015 Nov 14. PubMed PMID: 26584894. 14. Bourlière M, Adhoute X, Ansaldi C, Oules V, Benali S, Portal I, Castellani P, Halfon P. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol. 2015;9(12):1483-94. doi: 10.1586/17474124.2015.1111757. Epub 2015 Nov 23. PubMed PMID: 26595560. 15. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015 Oct;64(10):1605-15. doi: 10.1136/gutjnl-2014-306997. Epub 2014 Sep 11. PubMed PMID: 25214320. 16. Laquière A, Grandval P, Arpurt JP, Boulant J, Belon S, Aboukheir S, Laugier R, Penaranda G, Curel L, Boustière C. Interest of submucosal dissection knife for endoscopic treatment of Zenker's diverticulum. Surg Endosc. 2015 Sep;29(9):2802-10. doi: 10.1007/s00464-014-3976-x. Epub 2014 Dec 5. PubMed PMID: 25475517. 17. Million M, Hocquart M, Seghboyan JM, Griffiths K, Halfon P, Lagier JC, Brouqui P, Raoult D. Faecal microbiota transplantation as salvage therapy for fulminant Clostridium difficile infections. Int J Antimicrob Agents. 2015 Aug;46(2):227-8. doi: 0.1016/j.ijantimicag.2015.05.002. Epub 2015 Jun 3. PubMed PMID: 26092095. 18. Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29. PubMed PMID: 25926499; PubMed Central PMCID: PMC4473242. 19. Carcopino X, Camus C, Halfon P. [Diagnosis and clinical management of cervical HPV infections]. Presse Med. 2015 Jul-Aug;44(7-8):716-26. doi: 10.1016/j.lpm.2015.02.020. Epub 2015 Jun 9. French. PubMed PMID: 26067573. 20. Kessler HH, Cobb BR, Wedemeyer H, Maasoumy B, Michel-Treil V, Ceccherini-Nelli L, Bremer B, Hübner M, Helander A, Khiri H, Heilek G, Simon CO, Luk K, Aslam S, Halfon P. Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. J Clin Virol. 2015 Jun;67:67-72. doi: 10.1016/j.jcv.2015.03.023. Epub 2015 Mar 31. PubMed PMID: 25959162. 21. Adhoute X, Penaranda G, Raoul JL, Bourlière M. Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''. J Hepatol. 2015 Jun;62(6):1442-3. doi: 10.1016/j.jhep.2015.02.001. Epub 2015 Feb 9. PubMed PMID: 25678389. 22. Halfon P, Penaranda G, Mohamed S, Camus C, Khiri H. Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice. Eur J Gastroenterol Hepatol. 2015 May;27(5):557-60. doi: 10.1097/MEG.0000000000000326. PubMed PMID: 25822864. 23. Sertorio M, Hou X, Carmo RF, Dessein H, Cabantous S, Abdelwahed M, Romano A, Albuquerque F, Vasconcelos L, Carmo T, Li J, Varoquaux A, Arnaud V, Oliveira P, Hamdoun A, He H, Adbelmaboud S, Mergani A, Zhou J, Monis A, Pereira LB, Halfon P, Bourlière M, Parana R, Dos Reis M, Gonnelli D, Moura P, Elwali NE, Argiro L, Li Y, Dessein A. IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology. 2015 Apr;61(4):1321-31. doi: 10.1002/hep.27629. Epub 2015 Mar 10. PubMed PMID: 25476703. 24. Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015 Apr;62(4):855-62. doi: 10.1016/j.jhep.2014.11.014. Epub 2014 Nov 21. PubMed PMID: 25463541. 25. Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015 Mar 27;7(3):521-31. doi: 10.4254/wjh.v7.i3.521. Review. PubMed PMID: 25848475; PubMed Central PMCID: PMC4381174. 26. Adhoute X, Penaranda G, Bronowicki JP, Raoul JL. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. J Hepatol. 2015 Feb;62(2):492-3. doi: 0.1016/j.jhep.2014.08.035. Epub 2014 Sep 4. PubMed PMID: 25194894. 27. Halfon P, Pénaranda G, Ouzan D. A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success. J Hepatol. 2015 Jan;62(1):238. doi: 10.1016/j.jhep.2014.08.055. Epub 2014 Oct 13. PubMed PMID: 25308177. 2014 28. Philibert P, Khiri H, Pénaranda G, Camus C, Drogoul MP, Halfon P. High Prevalence of Asymptomatic Sexually Transmitted Infections among Men Who Have Sex with Men. J Clin Med. 2014 Dec 12;3(4):1386-91. doi: 10.3390/jcm3041386. PubMed PMID: 26237608; PubMed Central PMCID: PMC4470190. 29. Eckert C, Emirian A, Le Monnier A, Cathala L, De Montclos H, Goret J, Berger P, Petit A, De Chevigny A, Jean-Pierre H, Nebbad B, Camiade S, Meckenstock R, Lalande V, Marchandin H, Barbut F. Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes New Infect. 2014 Nov 8;3:12-7. doi: 10.1016/j.nmni.2014.10.003. eCollection 2015 Jan. PubMed PMID: 25755885; PubMed Central PMCID: PMC4337936. 30. Lafeuillade A, Wainberg M, Gougeon ML, Loes SK, Halfon P, Tissot-Dupont H. Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic. AIDS Res Ther. 2014 Aug 21;11:28. doi: 10.1186/1742-6405-11-28. eCollection 2014. PubMed PMID: 25165483; PubMed Central PMCID: PMC4145833. 31. Halfon P, Ouzan D, Asselah T, Renou C, Allègre T, Delasalle P, Lafeuillade A, Cadranel JF, Haddad N, Khiri H, Pénaranda G, Bourlière M; Iliade Investigators. Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: A prospective multicenter cohort. Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):720-6. Doi: 10.1016/j.clinre.2014.06.004. Epub 2014 Jul 14. PubMed PMID: 25034356. 32. Salmon-Ceron D, Arvieux C, Bourlière M, Cacoub P, Halfon P, Lacombe K, Pageaux GP, Pialoux G, Piroth L, Poizot-Martin I, Rosenthal E, Pol S. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. Liver Int. 2014 Jul;34(6):869-89. doi: 10.1111/liv.12363. Epub 2013 Nov 25. PubMed PMID: 24138548. 33. Khiri H, Camus C, Portugal M, Pénaranda G, Boyer S, Halfon P. Cytological and virological medium performance and stability assessment using the Cobas(®) 4800 HPV test (Roche Diagnostics) used in France. Ann Biol Clin (Paris). 2014 Apr 1;72(2):213-223. PubMed PMID: 24736142 34. Mohamed S, Penaranda G, Gonzalez D, Camus C, Khiri H, Boulmé R, Sayada C, Philibert P, Olive D, Halfon P. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure. AIDS. 2014 Apr 2; 28:1315-1324. PubMed PMID: 24698843. 35. Halfon P, Cacoub P. [Treatment of hepatitis C with new direct antiviral drugs: Towards a disease cure]. Rev Med Interne. 2014 Apr;35(4):219-21. doi: 10.1016/j.revmed.2013.12.017. Epub 2014 Feb 19. French. PubMed PMID: 24559772. 36. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014 Feb;34 Suppl 1:69-78. doi: 10.1111/liv.12423. PubMed PMID: 24373081. 37. Mohamed S, Ravet S, Camus C, Khiri H, Olive D, Halfon P. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients. J Med Virol. 2014 Mar;86(3):394-403. doi: 10.1002/jmv.23853. Epub 2013 Nov 19. PubMed PMID: 24248806. 38. Halfon P, Pénaranda G, Belgodére O. Taenia in the gastrointestinal tract after "figatellu" ingestion. Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):243-4. doi: 10.1016/j.clinre.2013.10.006. Epub 2013 Dec 30. PubMed PMID: 24388341 39. Seitz J, Horvilleur J, Curel L, Lacotte J, Maluski A, Ferracci A, Bremondy M, Rosier A, Monchi M, Penaranda G, Faure J, Beurtheret S, Pisapia A. Active or passive pulmonary vein in atrial fibrillation: is pulmonary vein isolation always essential? Heart Rhythm. 2014 Apr;11(4):579-86. doi: 10.1016/j.hrthm.2014.01.009. Epub 2014 Jan 10. PubMed PMID: 24418165. 2013 40. Bondada L, Rondla R, Pradere U, Liu P, Li C, Bobeck D, McBrayer T, Tharnish P, Courcambeck J, Halfon P, Whitaker T, Amblard F, Coats SJ, Schinazi RF. Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6325-30. doi: 10.1016/j.bmcl.2013.09.068. Epub 2013 Sep 30. PubMed PMID: 24135727. 41. Halfon P, Sandri MT, Raimondo A, Ravet S, Khiri H, Sideri M, Penaranda G, Camus C, Mateos Lindemann ML. Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays. BMC Infect Dis. 2013 Oct 24;13:499. doi: 10.1186/1471-2334-13-499. PubMed PMID: 24156822 42. Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020. Epub 2013 Sep 29. PubMed PMID: 24183313. 43. Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review. PubMed PMID: 23881840 44. Maor Y, Morali G, Bashari D, Pénaranda G, Schapiro JM, Martinowitz U, Halfon P. Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel. Haemophilia. 2013 Jan;19(1):150-6. 45. Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study. J Med Virol. 2013 Mar;85(3):472-82. 46. Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H, Pénaranda G, Sideri M, Sandri MT. HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Arch Virol. 2013 Jun;158(6):1143-9. 47. Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2013 Feb;20(2):95-102. 48. Ouzan D, Pénaranda G, Joly H, Halfon P. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta. J Hepatol. 2013 Jun;58(6):1258-9. 49. Kchouk FH, Gorgi Y, Bouslama L, Sfar I, Ayari R, Khiri H, Halfon P, Aouadi H, Jendoubi Ayed S, Ayed K, Ben Abdallah T. Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients. Viral Immunol. 2013 Feb;26(1):40-8. 50. Halfon P. Sexual transmission of HCV among monogamous heterosexual couples: Be careful with reassuring counseling messages. Hepatology. 2013 Feb 19. 51. Mohamed S, Raimondo A, Pénaranda G, Camus C, Ouzan D, Ravet S, Bourlière M, Khiri H, Dukan P, Olive D, Halfon P. Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS One. 2013 Apr 16;8(4) 52. Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P. [Prevalence of genotype-specific HPV infection among women in France: Implications for screening and vaccination]. Gynecol Obstet Fertil. 2013 May;41(5):305-13 53. Sancho-Garnier H, Tamalet C, Halfon P, Leandri F, Le Retraite L, Djoufelkit K, Heid P, Davies P, Piana L. HPV self-sampling or the pap-smear: A randomized study among cervical screening non-attenders from lower socio-economic groups in France. Int J Cancer. 2013 May 27. 54. Giorgetti C, Vanden Meerschaut F, De Roo C, Saunier O, Quarello E, Hairion D, Penaranda G, Chabert-Orsini V, De Sutter P. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies. Hum Reprod. 2013 Oct;28(10):2636-42. doi: 10.1093/humrep/det295. Epub 2013 Jul 25. PubMed PMID: 23887070. 2012 55. Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: Results from a multicenter study. J Med Virol. 2012 Dec 26. 56. Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Vaccine. 2012 Jul 27;30(35):5215-21. doi: 10.1016/j.vaccine.2012.06.013. 57. Halfon P, Ouzan D, Khiri H, Pénaranda G, Castellani P, Oulès V, Kahloun A, Amrani N, Fanteria L, Martineau A, Naldi L, Bourlière M. Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots. PLoS One. 2012;7(3):e33000. 58. Bataille S, Kaplanski G, Boucraut J, Halfon P, Camus C, Daniel L, Burtey S, Berland Y, Dussol B. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits. Am J Nephrol. 2012;35(2):134-40. 59. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 2012 Feb;32 Suppl 1:79-87. 60. Pasquier C, Andreutti C, Bertrand E, Bostan A, Bourlet T, Molina I, Grossman Z, Halfon P, Leruez-Ville M, Lüneborg-Nielsen M, Mar C, Marcelin AG, Roussel-Ronserail C, Schmitt MP, Tabrizi S, Vourliotis M, Bujan L. Multicenter assessment of HIV-1 RNA quantitation in semen in the CREAThE network. J Med Virol. 2012 Feb;84(2):183-7. 61. Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, Björkström NK, Malmberg KJ, Marcellin P, Vieillard V. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol. 2012 Feb;42(2):447-57. 62. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, Sideri M, Khiri H, Ravet S, Boyle S, Aldrich C, Halfon P. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn. 2012 Jan;14(1):65-70. 63. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012 Jan;35(1):92-104. 64. Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P; multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012 Jan;55(1):58-67. 2011 65. Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol. 2011 Dec 7;17(45):5007-13. 66. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011 Nov;34(10):1202-16. 67. Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, Pénaranda G, Tran A, Botta D, Oules V, Castellani P, Portal I, Argiro L, Dessein A. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):931-5. 68. Januel JM, Couris CM, Luthi JC, Halfon P, Trombert-Paviot B, Quan H, Drosler S, Sundararajan V, Pradat E, Touzet S, Wen E, Shepheard J, Webster G, Romano PS, So L, Moskal L, Tournay-Lewis L, Sundaresan L, Kelley E, Klazinga N, Ghali WA,Colin C, Burnand B; International Methodology Consortium for Coded Health Information (IMECCHI). [ICD-10 adaptation of 15 Agency for Healthcare Research and Quality patient safety indicators]. Rev Epidemiol Sante Publique. 2011 Oct;59(5):341-50. 69. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, Poynard T, Souberbielle JC, Cacoub P. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 2011 Oct;55(4):756-61. 70. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011 Jul;55(1):192-206. 71. Halfon P, Berger P, Khiri H, Martineau A, Pénaranda G, Merlin M, Faucher C. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. J Med Virol. 2011 Mar;83(3):490-5. 72. Halfon P, Cacoub P. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs]. Rev Med Interne. 2011 May;32(5):271-4. 73. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011 Aug 1;129(3):691-701. 2010 74. Halfon P, Benmoura D, Khiri H, Pénaranda G, Blanc B, Riggio D, Sandri MT. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. J Clin Virol. 2010 jan;47(1):38-42 75. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Pénaranda G, Blanc B. Relevance of HPV mRNA detection in a population of ASCUS + women using the NucliSENS EasyQ® HPV assay. J Clin Virol. 2010 Feb;47(2):177-181 76. Halfon P, Giorgetti C, Khiri H, Pénaranda G, Terriou P, Porcu-Buisson G, Chabert-Orsini V. Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One. 2010 May 13;5(5). 77. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol. 2010 Aug;48(4):246-50 78. Petit JM, Carrat F, Duong M, Halfon P, Duvillard L, Bani-Sadr F, Chavanet P, Cacoub P, Piroth L. Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect? Antivir Ther. 2010;15(5):797-800. 79. Sebastiani G, Tempesta D, Fattovich G, Castera L, Halfon P, Bourliere M, Noventa F, Angeli P, Saggioro A, Alberti A. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. J Hepatol. 2010 Jun 8 80. Poynard T, Munteanu M, Ngo Y, Castera L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, de Ledinghen V. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol. 2010 Aug-Sep;34(6-7):388-96 81. Calès P, Halfon P, Batisse D, Carrat F, Perré P, Penaranda G, Guyader D, d'Alteroche L, Fouchard-Hubert I, Michelet C, Veillon P, Lambert J, Weiss L, Salmon D, Cacoub P. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010 Aug;53(2):238-44 82. Cacoub P, Halfon P, Rosenthal E, Bailly F, Sadr FB, Benhamou Y, Chevaliez S, Pawlotsky JM, Piroth L, Yazdanpanah Y, Pol S. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. J Hepatol. 2010 Aug;53(2):230-7. 83. Halfon P, Martinot-Peignoux M, Khiri H, Marcellin P. Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability. Hepatology. 2010 Jul;52(1):401. 84. Mateos Lindemann ML, Morales JG, Fernández-Barredo S, Domínguez MR, García de la Hoz F, Halfon P, Pérez Gracia MT. Fulminant hepatitis E in a woman taking oral contraceptive medication. Am J Trop Med Hyg. 2010 Jan;82(1):12-5. 85. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (The FASE study). Int J Cancer. 2010 Oct 12. 86. Halfon P, Benmoura D, Agostini A, Khiri A, Penaranda G, Martineau A, Blanc B. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomarkers 2010; 7(3):133-9.. 87. Halfon P, Berger P, Khiri H, Martineau A, Penaranda G, Merlin M, Faucher C. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. J Med Virol. 2010. 83(3):490-5. 88. Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC; multicenter groups (SNIFF 14 & 17, ANRS HC EP 23 Fibrostar). Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43(16-17):1315-22 89. Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Pénaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group. Neutralizing antibodies to interferon-a and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-a-2a and ribavirin (ANRS HC16 GAMMATRI substudy). J Med Virol. 2010 Dec;82(12):2027-31 2009 90. Maor Y, Halfon P, Bashari D, Pénaranda G, Morali G, Klar R, Bar-Meir S, Martinowitz U, Oren R. Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C. Haemophilia 2009 Aug 21. [Epub ahead of print] 91. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guigen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. CpG methylation controls reactivation of HIV from latency. PloS Pathog. 2009 Aug;5(8):e10000554 92. Halfon P, Retornaz F, Mathieu D, Helbert T, Philibert P, Pégliasco H. Virus-associated hemophagocytic syndrome related to acute CMV and HBV sexual co-infection: A case report. J Clin Virol 2009 Jul 27. [Epub ahead of print] 93. Halfon P, Martinot-Peignoux M, Cacoub P. The myth of occult hepatitis C infection. Hepatology 2009 Jun 8. [Epub ahead of print] 94. Cacoub P, Halfon P. Virological monitoring of hepatitis C treatment in 2009. Rev Med Interne. 2009 Jun 12 [Epub ahead of print] 95. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourlière M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009 Jun;49(6):1812-7 96. Halfon P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Cacoub P. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study – ANRS HC02. Antivir Ther. 2009;14(2):211-9 97. Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C,Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P. Influence of insulin resistance on Hepatic Fibrosis and Steatosis in HCV Monoinfected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther. 2009 Mar 9. [Epub ahead of print] 98. Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirch I. Hepatitis C virus is a weak inducer of inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PloS One. 2009;4(2):e4319 99. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics. 2009 May;8(5):986-94 100. [Optimal virologic monitoring of hepatitis C in 2009: Treatment duration depends on the speed of virologic response and the duration of the negative reaction]. Presse Med. 2009;38(7-8):1037-40 101. Zvibel I, Halfon P, Fishman S, Pénaranda G, Leshno M, Or AB, Halpern Z, Oren R. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liver Int. 2009 Feb;29(2):208-12. 102. Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, Bourlière M, Sturm N, Foucher J, Oberti F, Rousselet MC, Calès P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterology Hepatol. 2009;21(1):28-38 103. Halfon P, Pénaranda G, Cacoub P. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insuline resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIBAVIC trial]. Gastroenterol Clin Biol. 2009 Mar;33 Suppl 2:S113-7. French 104. Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Pol S, Halfon P.Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther. 2009;14(6):839-45. 105. Martino-Peignoux M, Khiri H, Leclere L, Maylin S, Marcellin P, Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. J Clin Virol. 2009 Nov;46(3):216-21 2008 106. Zvibel I, Halfon P, Fishman S, Pénaranda G, Leshno M, Or AB, Halpern Z, Oren R. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liver Int. 2008 Aug 6. 107. Halfon P, Bourlière M, Khiri H, Pénaranda G, Martineau A, Oulès V, Courcambeck J, Philibert P. Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS. 2008 Aug 20;22(13):1694-6. 108. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Pénaranda G, Bréchot MC, Trocme C, Calès P. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: A meta-analysis with individual data. Clin Biochem. 2008 Jul 11. 109. Lambert J, Halfon P, Pénaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem. 2008 Aug;54(8):1372-8. 110. Bourliere M, Pénaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, Rosenthal E, Wartelle-Bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-Allieri MA, Halfon P. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther. 2008 Aug 15;28(4):458-67. 111. Halfon P, Bourlière M, Ouzan D, Sène D, Saadoun D, Khiri H, Pénaranda G, Martineau A, Oulès V, Cacoub P. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol. 2008 Jun;46(6):2106-8. 112. Renou C, Moreau X, Pariente A, Cadranel JF, Maringe E, Morin T, Causse X, Payen JL, Izopet J, Nicand E, Bourlière M, Pénaranda G, Hardwigsen J, Gerolami R, Péron JM, Pavio N; ANGH, France. A national survey of acute hepatitis E in France. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1086-93. 113. Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. J Hepatol. 2008 May;48(5):765-73. 114. Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroenterol Clin Biol.2008 Sep;32(6 Suppl 1):73-9. 115. Renou C, Cadranel JF, Pariente A, Pénaranda G, Bourlière M, Halfon P, Igual JP, Harafa A, Muller P, Bertrand JJ, Laugier R. Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers. Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1235-7. 116. Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison on non-invasive liver fibrosis biomarkers in HIV-HCV coinfected patients: the Fibrovic Study-ANRS HC02. J Hepatol. 2008 May;48(5):765-73. 2007 117. Halfon P, Bacq Y, De Muret A, Pénaranda G, Bourlière M, Ouzan D, Tran A, Botta D, Renou C, Brechot MC, Degott C, Paradis V. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46 : 395-402. 118. Halfon P, Trépo E, Antoniotti G, Bernot C; Cart-Lamy P, Khiri H, Thibaud D, Marron J, Martineau A, Pénaranda G, Benmoura D, Blanc B, RBML. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol 2007; 45 : 313-6. 119. P Halfon, M Bourlière, G Pénaranda, P Cacoub. Intérêts et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l’hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007; 36 : 547-66. 120. P Halfon, G Pénaranda, C Renou, M Bourlière. External Validation of FibroIndex. Hepatology 2007 ; 46 : 280-1. 121. Y Maor, P Calès, D Bashari, G Kenet, A Lubetsky, J Luboshitz, JM Schapiro, G Pénaranda, S Bar-Meir, U Martinowitz, P Halfon. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatits C- infected haemophilia patients. Haemophilia 2007; 13 : 722-29. 2006 122. P Halfon, N Limal, G Pénaranda, H Khiri, D Sene, M Andreu, JM Feryn, M Rotily, R Serra, JC Piette, P Cacoub. Chronic Chlamydia pneumoniae infection in patients with symptomatic atherothrombosis. Journal of Infection 2006 ; 53 :93-97 123. P Halfon, G Pénaranda, M Bourlière, H Khiri, MF Masseyeff, D Ouzan, Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. Journal of Medical Virology 2006; 78 : 208-15. 124. P Halfon, C Giorgetti, M Bourlière, V Chabert-Orsoni, H Khiri, G Pénaranda, JM Chincholle, Hervé Gallais, I Ravaux, J Moreau, JA Gastaud, R Roulier. Medically assisted procreation and transmission of hepatitis C virus : absence of HCV RNA in purified sperm fraction in HIV co-infected patients. AIDS 2006; 20 : 241-6. 125. P Halfon, M Bourlière, R Deydier, D Botta-Fridlund, C Renou, A Tran, I Portal, I Allemand, JJ Bertrand, A Rosenthal-Allieri, M Rotily, C Sattonet, T Benderitter, MC Saint-Paul, HP Bonnot, G Pénaranda, C Degott, MF Masseyeff, D Ouzan. Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterology 2006; 101:547-55. 126. P Halfon, M Bourlière, S Pol, Y Benhamou, D Ouzan, M Rotily, H Khiri, C Renou, G Pénaranda, D Saadoun, V Thibault, J Serpaggi, M Varastet, MH Tainturier, T Poynard, P Cacoub. Multicenter study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat. 2006;13(5):329-35. 127. C Renou, M Bourlière, F Martini, D Ouzan, G Pénaranda, O Larroque, A Harafa, JP Igual, B Calvet, S Sokolowsky, T Benderitter, P Halfon. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: complete biochemical and histological response to therapy with ursodesoxycholic acid. J Gastroenterol Hepatol. 2006;21(4):781-2. 128. P Halfon; M Bourlière, G Pénaranda, P Cacoub. Les marqueurs sanguins non invasifs de fibrose hépatique au cours de l’infection chronique par le virus de l’hépatite C. Rev Med Interne 2006 ; 27 : 751-61. 129. P Halfon, M Bourlière, G Pénaranda, H Khiri, D Ouzan. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol. 2006;44(7):2507-11. 130. Y Maor, D Bashari, G Kenet, A Lubetsky, J Luboshitz, JM Shapiro, G Pénaranda, S Bar-Meir, U Martinowitz, P Halfon. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006;12(4):372-9. 131. M Bourlière, G Pénaranda, C Renou, D Botta-Fridlund, A Tran, I Portal, L Lecomte, P Castellani, MA Rosenthal-Allieri, R Gerolami; D Ouzan, R Deydier, C Degott, P Halfon. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver fibrosis. J Viral Hepat 2006; 13 (10) ; 659-70. 2005 132. P Halfon, M Bourlière, G Pénaranda, R Deydier, C Renou, D Botta-Fridlund, A Tran, I Portal, I Allemand, A Rosenthal-Allieri, D Ouzan. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comparative Hepatology 2005; 11: 4:6. 133. P Halfon, G Pénaranda, H Khiri, B Xeridat. Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption. AIDS 2005; 15: 1713-4. 134. D Ouzan, H Khiri, G Pénaranda, H Joly, P Halfon. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype I patients. Comparative Hepatology 2005; 4 : 1-5. 2004 135. J Deval, L Kirsten, White, D Michael, Miller, T Neil, Parkin, J Courcambeck, S Selmi, P Halfon, J Boretto, B Canard. Mechanistic Basis for Reduced Viral an Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations. Journal of Biological Chemistry 2004; 279 : 509-16. 136. J Deval, JM Navarro, B Selmi, J Courcambeck, J Boretto, P Halfon, S Garrido-Urbani, J Sire, B Canard. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. Journal of Biological Chemistry 2004; 279 : 25489-96. 137. P Halfon, D Ouzan, L Cattan, P Cacoub. Un point de vue pluridisciplinaire sur l’infection par le VHC. La Presse Médicale 2004; 33: 544-9. 138. P Halfon, D Ouzan, L Cattan, P Cacoub. Les outils du pronostic de l’infection par le virus de l’hépatite C. La Presse Médicale 2004; 33: 542-3 139. P Halfon, D Ouzan, L Cattan, P Cacoub. Les outils du diagnostic de l’infection par le virus de l’hépatite C. La Presse Médicale 2004; 33: 538-41. 140. C Renou, P Halfon. High-Risk Behavior and Sexual Transmission of Hépatitis C. American Journal of Gastroentérology 2004. 141. E Brunelle, S Ledru, M Rotily, C Becker, T Davion, V Vosgien, M Martinot, and P Halfon. Spontaneous clearance of hepatitis C Virus after long-term opiate dependence therapy with buprenorphine. Journal of Viral Hepatitis, 2004, 11: 571-3. 2003 142. P Halfon, A U Neumann, M Bourlière, A Rieu, S Chadapaud, H Khiri, D Ouzan, P Cacoub. Slow Viral Dynamics of Hepatitis C Genotype 4. Journal of Viral Hepatitis 2003; 10 : 351-3. 143. P Halfon, H Khiri, A Tran, H Joly, D Ouzan. Hepatitis C virus RNA load in relapsed patients : week two of treatment the best time to predict the complete response. Journal of Gastroenterologie Hepatology 2003; 15 : 1067-71. 144. P. Halfon, J. Durant, P. Clevenbergh, H Carsenti, L. Celis, H. Khiri, K. De Smet, A. De Brauwer, F. Hulstaert, P. Dellamonica.. Kinetics of disappearance of resistance mutations and reapperance of wilde-type during structured treatment interruptions. AIDS 2003;17: 1351-61. 145. P. Halfon, S Pol, M Bourlière, J Coucambeck, P Cacoub. Résistance aux analogues de nucleosides dans le traitement de l'hépatite chronique B. La revue de médecine interne 2003; 24 : 786-93. 146. C Solas, A Lafeuillade, P Halfon, S Chadapaud, G Hittinger, B Lacarelle. Discrepancies Between Protease Inhibitor Concentrations and Viral Load in reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents Chemotherapy 2003 ; 47 : 238-43. 147. P Cacoub, M bourlière, P Hausfater, F Charlotte, H Khiri, S Toci, JC Piette, T Poynard, P Halfon. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection. Journal of Viral Hepatitis 2003 ; 10 : 10-5. 148. P Cacoub, E Rosenthal, V Gerolami, P Hausfater, P Ghillani, Y Sterkers, V Thibault, H Khiri, JC Piette, P Halfon. Transfusion-associated TT virus co-infection in patients with hepatitis C virus is associated with type II mixed cryoglobulinemia but not with B-cell non-Hodgkin lymphoma. Clin Microbiol Infect 2003 ; 9 : 39-44. 149. C Renou, A Harafa, C Cummins, P Muller, C Dematteï, E Jouve, JJ Bertrand, P Halfon. Threshold for Neutropenia in the Adjustment of Interferon Treatment in HCV Infection. Hepatology 2003; 37 : 949. 150. C Chiaverini, G Halimi, D Ouzan, P Halfon, JP Ortonne, JP Lacour. Porphyria cutanea tarda, C282Y, H63D and S65C HFE Gene Mutations and Hepatitis C infection : A Study from Southern France. Dermatology 2003 ; 206 : 212-6. 151. I Portal, M Bourlière, P Halfon, P Couzigou, PH Bernard, F Blanc, F Caroli-Bosc, JP Arpurt, D Vetter, C Mathieu-Chandelier, O Chazouillères, G Thiefin, S Pol, P Sogni, A Abergel, F Bailly, M Picon, JM Debonne, C Zamora, I Alleman, X Moreau, F Doll, C Eugène, S Ducloux, D Larrey, D Ouzan, JC Grimaud, J Gouvernet, G Botti, V Gérolami, H Khiri, A Gérolami, AP Gauthier, D Botta-Fridlund. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C Patients : a prospective multicentre randomized controlled study. Journal of Viral Hepatitis 2003 ; 10 :215-23. 152. PM Roger, J Durant, M Ticchioni, P Halfon, JP Breitmayer, B Brignone, S Chaillou, B Dunais, P Dellamonica, A Bernard. Apoptosis and proliferation kinetics of T cells in patients having experienced antiretroviral treatment interruptions. J Antimicrob Chemother 2003 ; 52 : 269-75. 153. P Halfon, H Khiri. A Tran, G Perandea, J Courcambeck, H Joly, D Ouzan. Hepatitis C virus RNA load in relapsed patients : week two of treatment is the best time to perdict the complete response. European Journal of Gastroenterology and Hepatology 2003 ; 15: 1067-71. 154. P Muller, C Renou, A Harafa, E Jouve, G Kaplanski, E Ville, JJ Bertrand, C Masson, T Benderitter, P Halfon. Lymph node enlargement within the hepatoduodenal ligament in patients with chronic hepatitis C reflects the immunological cellular response of the host. Journal of Hepatology. 2003; 39: 807-13. 2002 155. M Bourlière, JM Barberin, M Rotily, V Guagliardo, I Portal, L Lecomte, S Benali, C Boustière, H Perrier, M Jullien, G Lambot, R Loyer, O Le Bars, R Daniel, H Khiri, P Halfon. Epidemiological changes in hepatitis C virus genotypes in France : evidence in intravenous drug users. Journal Viral Hepatitis 2002 : 9; 62-70. 156. C Renou, P Halfon, S Pol, P Cacoub, E Jouve, JP Bronowiki, JP Arpurt, H Rifflet, , M Picon, X Causse, V Canva, J Denis, A Tran, M Bourlière, D Ouzan, A Pariente, S Dantin, L Alric, V Cartier, M Reville, S Caillat-Zucman. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-90. 157. S Hüe, P Cacoub, C Renou, P Halfon, V Thibault, F Charlote, M Picon, H Rifflet, JC Piette, S Pol, S Caillat-Zucman. Human Leukocyte antigen Class II Alleles May Contribute to the Severity of Hepatitis C Virus-Related Liver Disease. The Journal of Infectious Diseases 2002; 186 : 106-9. 158. P Halfon, C Roubicek, V Gerolami, Y Quentin, H Khiri, G Pepe, Y Berland. The use of phylogenetic analysis of HCV-HVR1 sequences to trace an outbreak of HCV in an autodialysis unit. Journal of Clinical Microbiology 2002 ; 40 : 1541-5. 159. P Trimoulet, P Halfon, H Khiri, H Fleury. Performance Evaluation of the VersantTM HCV RNA 3.0 assay for quantification of serum Hepatitis C Virus RNA. Journal of Clinical Microbiology 2002; 40: 2031-6. 160. M Bourliere, P Halfon, I Portal. Conference Française de consensus sur le VHC Traitement des groupes particuliers. Gastoenterol Clin et Biol 2002; 26: B 238-47. 161. V Leroy, M Bourlère, M Durand, A Abergel, A Tran, M Baud, D Botta-Fridlund, A Gérolami, D Ouzan, P Halfon, JP Zarski. The antibody response to hepatitis B virus vaccination is negatively influenced by the HCV viral load in patients with chronic hepatitis C : a case control study. European Journal of Gastroenterology 2002; 14 : 485-9. 162. P Cacoub, M Bourlière, P Hausfater, H Khiri, S Toci, J C Piette, T Poynard, P Halfon. Lower expression of CD81 B cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection. Journal of Viral Hepatitis 2002; 9: 1-5 163. P Halfon, M Bourlière, H Khiri, G Halimi, V Gerolami, JM Feryn, D Ouzan. Serological response to infection with different isolates of hepatitis C virus. Journal of Viral hepatitis 2002; 9; 438-42. 164. P. Cacoub, E. Rosenthal, V. Gerolami, P. Hausfater, N. Costedoat-Chalumeau, P. Ghillani, Y. Sterkers,V. Thibault, H. Khiri, J.C. Piette and P. Halfon. Transfusion-associated TT virus coinfection in patients with hepatitis C virus is associated with type II mixed cryoglobulinemia but not with B-cell non-Hodgkin lymphoma. Clinical Microbiology and infection, 2002, 8. 1-6 165. C. Renou, A. Harafa, R. Bouabdallah, C. Demattei, C. Cummins, H. Rifflet, P. Muller, E. Ville, J. Bertrand, T. Benderitter, P. Halfon. Severe Neutropenia and Post-Hepatitis C cirrhosis treatment : is interferon dose adptation at once necessary ? American Journal of Gastroenterology 2002; 97 (5): 1260-63. 166. G Pépe, G Giuliani, S Loustalet, P Halfon. Hydration free energy a fragmental model and drug design. European Journal of Medicine Chemistry 2002; 37: 865-72. 167. P Halfon, S Pol, M Bourlière P Cacoub. Les génotypes du virus de l’hépatite B. Gastroentérologie Clinical Biology 2002 ; 26 : 1005-12. 168. P Halfon, F Imbert-Bismuth, D Messous, G Antoniotti, D Benchétrit, P Cart-Lamy, G Delaporte, D Doutheau, T Klumpp, M Sala, D Thibaud, E Trépo, D Thabut, RP Myers, T Poynard. A prospective assessment of Inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comparative Hepatology 2002; 1 : 3 : 1-10. 169. C Renou, S Pol, P Halfon, S Caillat-Zucman. Controversies about the histological features of chronic HCV patients with persistently normal alamine transaminases levels: what can be done about the present definition. Gastroenterology 2002; 123 : 1748-9. 2001 170. P Halfon, H Rifflet, C Renou, Y Quentin, P Cacoub. Molecular evidence of male to female sexual transmision of hepatitis C virus after vaginal and anal intercourse. J Clin Microbiol 2001; 39 : 1204-6. 171. P Halfon, P Trimoulet, M Bourlière, H Khiri,V de Lédinghen, P Couzigou, JM Feryn, P Alcaraz, C Renou, HJA Fleury, D Ouzan. Hepatitis C virus genotyping based on 5’ non coding sequence analysis (Trugene TM). J Clin Microbiol 2001 ; 39 : 1771-3. 172. C Renou, P Muller, E Jouve, JJ Bertrand, A Raoult, T Benderitter, P Halfon. Relevance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. American Journal Gastrorenterology 2001 ; 5 : 1657-9. 173. A Lafeuillade, P Halfon, S Chapadaud, G Hittinger, H Khiri, C Poggi. Potential adverse effects of structured therapeutic interruptions on the pool of HIV-Infected cells. Journal of Acquired Immune Deficiency Syndromes; vol 28 n° 2, October 1, 2001.197-9. 174. A Lafeuillade, H Khiri, S Chapadaud, G Hittinger, P Halfon. Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART. AIDS 2001, 15: 1965-1969. 175. P Halfon. Bases de la variabilité genetique du VHC. Iléus n° 10 novembre/décembre 2001. 176. A Lafeuillade, C Poggi, S Chapadaud, G Hittinger, H Khiri, P Halfon. Impact of immune interventions on HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV medicine (2001) 2, 189-194. 2000 177. P Halfon, P Cacoub. Quantification virale du virus de l’hépatite C : présent et avenir. Revue de Médecine Interne 2000 ; 21 :174-81. 178. E Debono, P Halfon, M Bourlière, V Gérolami-Santandrea, M Gastaldi-Plannels, P Castellani, G Cartouzou, D Botta-Fridlund, P Cau, A.Gauthier. Absence of detection of hepatitis C genome in semen of infected men by polymerase chain reaction, branched DNA and in situ hybridation Hepatology Liver 2000 ; 20 : 257-61. 179. P Halfon, G Halimi, M Bourlière, D Ouzan, J Durand, H Khiri, L Mercier, V Gérolami, G Cartouzou. Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non responders to interferon therapy. Liver 2000 ; 20 : 381-86. 180. J.J Lefrere, J Lerable, M Mariotti, M Bogard, V Thibault, L Frangeul, P Loiseau, F Bouchardeau, S Laperche, J.M Pawlotsky, J.F Cantaloube, P Biagini, X de Lamballerie, J Izopet, C Defer, I Lepot, J.D Poveda, E Dussaix, V Gérolami, P Halfon, C Buffet-Janvresse, C Ferec, B Mercier, P Marcellin, M Martinot-Peignoux, M Gassain. Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virusC (GBV-C) hepatitisG virus (HGV) polymerase chain reaction assay. J Virol Methods 2000 ; 85 (1-2) :117-24. 181. M Bourlière, P Halfon, Y Quentin, P David, C Mengoti, I Portal, H Khiri, S Benali, H Perrier, C Boustière, M Jullien, G Lambot. Covert Transmission of Hepatitis C During Fisticuffs. Gastroenterology 2000 ; 119 : 507-11. 182. J Durant, P Clevenbergh, R Garraffo, P Halfon, S Icard, P Del Giudice, N Montagne, JM Schapiro, P Dellamonica. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy : pharmacological data from the Viradapt Study. Aids 2000; 14 : 1-7. 183. P Clevenbergh, J Durant, P Halfon, P del Giudice, V Mondain, N Montagne, JM Schapiro, CAB Boucher, P Dellamonica. Persisting long-term benefit of genotype-guided tratment for HIV-infected patients failing HAART. The Viradapt study : week 48 follow-up. Antiviral Therapy 2000 ; 5 : 65-70. 1999 184. P Halfon, M Bourlière, JM Feryn, H Khiri, M Chanas, JM Salvadori, D Ouzan . Prevalence of transmitted transfusion virus (TTV) in populations at different risk for hepatitis virus: hemodialysis, chronic hepatitis C and cryptogenetic hepatitis patients. J Hepatol 1999; 30 : 552. 185. P Cacoub, P Halfon, L Musset. Transfusion-transmitted virus and mixed cryoglobulinemia. Ann Intern Med 1999 ; 130 : 451-2. 186. B Mercier, A Barclais, C Botte, JF Cantalube, J Coste, C Defer, C.Gautreau, C Giannoli, P Halfon, I Lepot, P Loiseau, J Martial, P Montcharmont, P Merel, D Ouzan, N Ravera, J Follana, R Césaire C Janot, JM Lemaire, P De Micco, G Vezon, C Férec. Prevalence of GBV C/HGV RNA and GBV C/HGV antibodies in french volunteer blood donors : Results of a collaborative study.Journal of Virological Methods 1999 ; 76 : 166-69. 187. P Halfon, P Cacoub. Quantification virale C : présent et avenir. La lettre de l’hépato-gastro 1999 ; 2 :140-50. 188. P Halfon, Y Quentin, B Roquelaure, J Sarles, G Halimi, V Gérolami, H Khiri, M Bourlière, G Cartouzou. Mother-to-infant transmission of hepatitis C virus : molecular evidence of superinfection by homologous virus in children. Journal of Hepatology 1999 ; 30 :970-78. 189. P Halfon, P Cacoub. Le virus TTV : un nouveau virus hépatotrope à la recherche d’une maladie. La presse médicale 1999 ; 28 :1592-94. 190. J Durant, P Clevenbergh, P Halfon, P Del Giudice, S Porsin, P Simonet, N Montagne, C.A.B Boucher, J.M Schapiro, P Dellamonica. Improving HIV Therapy with drug resistance genotyping : the VIRADAPT randomised study. Lancet 1999 ; 353 : 2195-99. 191. M Bourlière, I Portal, P Halfon. Que dire, que faire, en cas de contamination accidentelle par le virus. Hépato-gastro 1999 ; 6 :46-48. 192. D Ouzan, P Halfon. Le TTV : Un nouveau virus des hépatites ? La revue du praticien 1999 ; 13 : 1507-08. 193. M Martinot-Peignoux, F Roudot-Thoraval, I Mendel, J Coste, P Halfon, J Izopet, G Duverlie, C Payan, JM Pawlotsky, C Defer, M Bogard, V Gérolami, Y Buisson, B Fouqueret, P Loiseau, J Lamoril, JJ Lefrère, P Marcellin. Hepatitis C virus genotypes in France : relationship with epidemiology, pathogenicity and response to Interferon therapy. Journal of Viral Hepatitis 1999 ; 6 :435-43. 1998 194. P Halfon, M Bourlière, G Halimi, H Khiri P Berthezene, I Portal, D Botta-Fridlund, AP Gauthier, M Jullien, JM Feryn, V Gérolami, G Cartouzou,. Assessment of Spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by twxo standardized quantitation methods: Branched DNA and Amplicor monitor. Journal of Clinical Microbiology 1998 ; 36 : 2073-5. 195. J Durant, P Chantre, G Gonzales, L Montagnier, J Vandermander, P Halfon, B Rousse, Rahelinirina, J Dellamonica. Efficacity and safety of SPV 30 in HIV infected asymptomatic patients: a multicentre, randomized, double mind, placebo-controlled trial. International Journal of Phytotherapy and Phytopharmacology 1998; 5 : 1-10. 196. P Halfon, H Khiri, JM Feryn, C Sayada, M Chanas,. D Ouzan Prospective virological folow up of hepatitis C infection in ahaemodialysis unit. Journal of Viral Hepatitis 1998 ; 5 : 115-21. 197. P Halfon, G Halimi, V Gérolami, C Sayada, G Cartouzou. Hépatite C : Apport de la quantification virale. Feuillets de Biologie 1998 ; 224 : 29-37. 198. P Halfon, M Bourlière. Diagnostic de l’infection virale C : pratiques et collaboration biologistes-médecins. Actualité Médicale Internationales Gastroentérologie 1998 ; 12 : 6-10. 199. V Gérolami, P Halfon, H Chambost, I Thuret, G Halimi. Transfusion transmitted virus. Lancet 1998; 352 : 1309. 200. P Clevenbergh, J Durant, P Halfon, A Tran, T Manos, V Rahelinirina, G Yang, S Benzakeen, D Ouzan, P Rampal and P Dellamonica. High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients. Clinical Microbiology Infectious 1998 ; 4 : 644-47. 1997 201. F Lunel, H Poinsot, M Bogart, C Brechot, C Defer, G Duverlie, B Fouqueray, P Halfon, P Lewine, P Loiseau, P Marcellin, JP Zarski, L Stuyver. Prevalence and characteristics of genotype 2 subtypes in France in:hepatitis C virus genetic heterogenity and viral load, GEMHEP, John Libbey Eurotext, Paris 1997: 111-114. 202. P Halfon, H Khiri, V Gérolami, J.PAlimi, G Halimi, J.M Feryn, S Legros, M Bourlière, J Sarles, G Cartouzou. Molecular evidence of mother-to-infant transmission of hepatitis C by quasispecies analysis. in: Hepatitis C virus genetic heterogeneity and viral load. GEMHEP. John Libbey Eurotext, Paris. 1997: 115-18. 203. P Halfon, G Cartouzou, D Ouzan. Les nouveaux virus des hépatites: le virus G/ GBV-C. La revue du Praticien-Médecine Générale 1997, 11: 21-3. 204. D Ouzan, P Halfon, M Chanas, H Khiri, JM Feryn, JM Salvadori. Relevance of hepatitis C virus RNA detection, quantification, and genotypes in hemodialysis patients. European Journal of Internal Medecine 1997; 8 : 89-93. 205. P Halfon, D Ouzann H Khiri, JM Feryn,. Serotyping and genotyping of Hepatitis C strains in chronic HCV infection. Journal of Medical Virology 1997; 52 : 391-5. 206. M Rotily, S Loubière, J Nixon, M Bourlière, P Halfon, JP Moatti. Analyse économique des différentes stratégies possibles de dépistage de l’hépatite chronique C. Gastroenterologie Clinique et Biologique 1997; 20 : S33-S40. 207. P Halfon, G Cartouzou, M Bourlière. Les génotypes du virus de l'hépatite C: quels intérêts en pratique? Hepato-Gastro 1997; 4 : 295-303. 208. P Halfon, S Pol, C Sayada, J Izopet, L Rostaing, D Ouzan. Intérêt de la Recherche et la quantification de l'ARN du virus de l'hépatite C chez les hémodialysés : proposition d'une stratégie diagnostique rationnelle. Néphrologie 1997; 18 : 53-8. 209. P Halfon, M Bourlière, JJ Raabe, H Khiri, V Gérolami, G Cartouzou, JM Feryn, , D. Ouzan. Transmission of Hepatitis G virus in HCV-infected couples : myth or reality ? Journal of Hepatology 1997; 23: 427. 210. V Gerolami, P Halfon, H Chambost, F Sicardi H Thuret, R Planells, G Halimi, C Fossat, G Michek, G Cartouzou. Prevalence of hepatitis G virus RNA ina monocentric population of French haemophiliac.. British Journal of Haematology 1997; 99 : 209-214. 211. M Bogard, C Buffet-Janvresse, JF Cantaloube, P Biagini, G Duverlie, S Castelain, J Izopet, M Dubois, C Defer, I Lepot, J Coste, P Marcellin, M Martinot-Peignoux, P Halfon, V Gerolami, L Frangeul, JM Pawlotsky, F Roudot-Thoraval, E Dussaix, P Loiseau, N Ravera, P Lewin, J Lamoril, J Lerable, P Lebon. Multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum GEMHEP. Journal of Clinical Microbiology 1997; 35 : 3298-3300. 1996 212. P Halfon, H Khiri, V Gérolami, JM Feryn, P Reynier P, M Bourlière, A Gauthier, G Cartouzou. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. Journal of Hepatology 1996; 25 : 307-11. 213. P Halfon, D Ouzan, M Chanas, H Khiri, JM Feryn, L Mangin and JM Salvadori. Role of hepatitis C viral infection on Hepatitis E transmission in hemodialysis patients. Enterically-Transmitted Hepatitis Viruses. Y Buisson, P Cousaget and M Kane, editors 1996; 230-1. 214. D Ouzan, P Halfon, H Khiri, C Tirtaine, L Mangin, J.M Feryn and R Follana. Interest of HEV Antibody screening in French Blood Donnors with elevated ALT. Enterically-Transmitted Hepatitis Viruses Y Buisson, P Cousaget and M Kane, editors 1996; 235-6. 215. P Halfon, M Levy, M San Marco, V Gérolami, H Khiri, M Bourlière, JM Feryn, JL Gastaut, J Pouget, G Cartouzou. Myasthenia gravis and hepatitis C virus infection. Journal of Viral Hepatitis 1996; 3 : 329-332. 1995 216. P Halfon, D Ouzan. Les nouveaux tests de la réplication du VHC. La Revue du Praticien -Médecine générale 1995; 9 : 26-32. 217. JF Rey, P Halfon, JL Feryn, H Khiri, MF Masseyeff, D Ouzan. Risque de transmission du virus de l'hépatite C par endoscopie digestive. Gastroentérologie Clinique et Biologique 1995; 19 : 346-349. 218. H Chambost, V Gérolami, P Halfon, I Thuret, G Michel, F Sicardi, S Rousseau, H Perrimond, G Cartouzou. Persistent hepatitis C virus RNA replication in haemophiliacs: role of co-infection with human immunodeficiency virus.. British Journal Haematology 1995; 91 : 703-07. 1994 219. P Halfon, D Ouzan, M Chanas, H Khiri, JM Feryn, L Mangin, MF Masseyef and JM Salvadori. High Prevalence of HEV Antibody in Hemodialysis Patients. Lancet 1994; 344 : 746. 220. D Ouzan, S Benzaquin, P Halfon. Qui vacciner contre l'hépatite B en France ? La Revue du Praticien - Médecine générale 1994; 8 : 258. 1993 221. V Gérolami, P Halfon, M Bourlière, H Khiri, P Reynier, PP Garnier, I Portal, A Gauthier, G Cartouzou. Hepatitis C virus genotypes in chronic hepatitis and response to interferon alfa therapy. Journal of Infectious Diseases 1993; 168 : 1328-9. 222. M Levy, P Halfon, V Gérolami, M Bourlière, et G Cartouzou. Détection de l'ARN du virus de l'hépatite C par PCR. Feuillets de Biologie 1993; 195: 53-60. 1992 223. P Halfon, S Rousseau, C Tamalet, M Antoni, V Gérolami, M Lévy, M Bourlière, R Planells and G Cartouzou. Indeterminate second generation hepatitis C recombinant immunoblot test : detection of hepatitis C virus infection by polymerase chain reaction. Journal of infectious Diseases 1992; 166 : 449. 1991 224. J Jacquemier, F Penaut, M Durst, P Parc, B Seradour, P Meynard, P Halfon and J Hassoun. Detection of five Different Human Papillomavirus Types in Cervical Lesions by in situ hybridization. Human pathology 1991; 21 : 911-17.
Areas of activity
Medical diagnostic / companion diagnostic
Skills
Biochemistry
Biology
Genomics
Hematology / cytology
Immunology
Microbiology
PCR
Pathologies
Infectiology
Oncology
Technologies
Biochemistry (in vitro)
Genetic testing
Immunology (in vitro)
Molecular biology, structural and cellular (in vitro)
Address:
1 rue Melchior Guinot
13003 MARSEILLE
Country: France
Web site:
Cluster:
Eurobiomed
Contact Contact member